Rate My Professor Takashi Tenma

Temma's research specializes in the development of imaging probes for positron emission tomography (PET), single photon emission computed tomography (SPECT), and fluorescence imaging, with a focus on boron neutron capture therapy (BNCT), tumor-specific delivery, and theranostics targeting pathways such as LAT1, p38α, and STAT3. Notable publications include "A LAT1-selective PET tracer, 5-[¹⁸F]F-αMe-3BPA, as a companion to its structurally matched ¹⁰B analog in boron neutron capture therapy" (Kondo et al., European Journal of Nuclear Medicine and Molecular Imaging, 2026), "Fluorine-18-Labeled Positron Emission Tomography Probe Targeting Activated p38α: Design, Synthesis, and In Vivo Evaluation in Rodents" (Futatsugi et al., Pharmaceuticals, 2025), "Assessing the effectiveness of fluorinated and α-methylated 3-boronophenylalanine for improved tumor-specific boron delivery in boron neutron capture therapy" (Hirano et al., Bioorganic Chemistry, 2024), and "Synthesis and evaluation of [18F]FBNAF, a STAT3-targeting probe, for PET imaging of tumor microenvironment" (Miyazaki et al., EJNMMI Radiopharmacy and Chemistry, 2024). He has received prestigious awards such as the Springer Nature Editor of Distinction Award (2025), Certificate of Commendation from GlaxoSmithKline K.K. (2019), Japan Brain Neuro-Nuclear Medicine Research Encouragement Award (2016), and SNMMI 62nd Annual Meeting Poster Award (2015). Temma has been principal investigator on multiple JSPS Grants-in-Aid for Scientific Research, including projects on BNCT agents and Cherenkov light-driven molecular machines during his time at Osaka University of Pharmaceutical Sciences. He holds editorial and directorial roles in societies like the Japanese Society of Nuclear Medicine and Japan Molecular Imaging Society, contributing to the field of nuclear medicine and pharmaceutical sciences.